Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest congenital heart disease Stories

2010-06-24 04:00:00

JENA, Germany, June 24, 2010 /PRNewswire/ -- In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent. AGA asked for permission to appeal to the...

2010-06-17 08:47:00

PHILADELPHIA, June 17 /PRNewswire-USNewswire/ -- Signaling a new frontier in the treatment of congenital heart disease (CHD), The Children's Hospital of Philadelphia is the first hospital in our region to implant transcatheter pulmonary heart valves in children with heart defects. This minimally invasive procedure gives patients a non-surgical option in their ongoing treatment. The Melody®( )Transcatheter Pulmonary Valve benefits patients with congenital heart defects...

2010-06-16 07:34:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it will participate in the Sidoti & Company, LLC 2010 Semi Annual New York Micro-Cap Conference at The Grand Hyatt Hotel. Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present a corporate overview on Friday, June 25, 2010 at 10:00 a.m., Eastern Time. A copy of CryoLife's...

2010-06-08 07:34:00

ATLANTA, June 8 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoValve® SG pulmonary human heart valve processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and...

2010-06-07 07:34:00

ATLANTA, June 7 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company whose products include BioGlue Surgical Adhesive, announced today that it has completed the purchase of U.S. patent # 6,329,337. The patent involves the formulation and use of recombinant human serum albumin and gluteraldehyde, and now becomes part of CryoLife's protein hydrogel patent portfolio, which includes BioGlue. "CryoLife will...

2010-06-03 09:00:00

LINCOLNSHIRE, Ill., June 3 /PRNewswire/ -- A congenital heart defect survivor is pedaling his bike across America, beginning June 8, 2010, to raise awareness about congenital heart defects and raise $100,000 in research dollars for the Children's Heart Foundation (CHF). To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/childrensheartfoundation/44443/ (Photo: http://www.newscom.com/cgi-bin/prnh/20100603/MM14402) "BIKE 4 CHF" --...

2010-06-01 07:06:00

ATLANTA, June 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that its Board of Directors has authorized the purchase of up to $15 million of its common stock over the course of the next two years, beginning no earlier than June 2, 2010. The purchase of shares will be made from time to time in the open market or through privately negotiated transactions on such terms as management...

4fdcdbd0e87c4f5e7462e46f76fb6fe61
2010-05-28 07:25:00

Although congenital heart disease represents the most common major birth defect, scientists have not previously identified the genes that give rise to it. Now genetics and cardiology researchers, two of them brothers, have discovered a genetic variant on chromosome 5 that strongly raises the risk of congenital heart disease. "This gene, ISL1, plays a key role in regulating early cardiac development, so there is a compelling biological reason for investigating it as a genetic risk factor for...

2010-05-27 14:38:45

Was largest clinical trial to compare surgical treatments for congenital heart disease Pediatric researchers report that a recently introduced surgical procedure offers infants with severely underdeveloped hearts a better chance at surviving during their first year of life, in comparison to the standard surgery. Heart surgeons from 15 centers in the federally sponsored Pediatric Heart Network studied the outcomes in 549 newborns who received a complex series of surgeries for hypoplastic left...

2010-05-27 14:22:31

National study led by the University of Michigan's Congenital Heart Center A trial on shunts used to direct blood flow to the lungs, led by researchers at the University of Michigan's C.S. Mott Children's Hospital, will lead to better outcomes for kids worldwide born with hypoplastic left heart syndrome, the most common severe heart birth defect. Under the leadership of the University of Michigan, the first multi-institutional randomized prospective trial ever conducted in congenital heart...


Latest congenital heart disease Reference Libraries

Echocardiogram
2013-07-29 11:11:00

An echocardiogram is a test that, much like an ultrasound, uses sound waves to create a moving image of the heart. The most common type of echocardiogram is performed transthoracic, meaning the image is taken through a probe against the chest. A TTE does not involve radiation and is a very safe procedure. A cardiac sonographer will put a gel on the patient's chest and move the transducer around different areas, including directly anterior to the breastbone, inferior and lateral to the right...

More Articles (1 articles) »